Elusys awarded additional $14.5 million under existing U.S. government contracts supporting expanded human safety studies of ETI-204 for treatment of inhalational anthrax

Media Center PRESS RELEASE 2012 ELUSYS AWARDED ADDITIONAL $14.5 MILLION UNDER EXISTING U.S. GOVERNMENT CONTRACTS SUPPORTING EXPANDED HUMAN SAFETY STUDIES OF ETI-204 FOR TREATMENT OF INHALATIONAL ANTHRAX Elusys to launch three human safety studies, including safety of ETI-204 administered via intramuscular injection (IM) PINE BROOK, NJ – SEPTEMBER 13, 2012 – Elusys Therapeutics, Inc. (Elusys), […]

Elusys picks up $50.2M BARDA funds to advance anthrax antitoxin

Media Center PRESS RELEASE 2012 Elusys picks up $50.2M BARDA funds to advance anthrax antitoxin 03 August 2012 Donna YoungWashington EditorScrip Elusys Therapeutics scored another $50.2 million under a broader contract with the US government to advance the development of the privately held firm’s experimental inhalational anthrax antitoxin Anthim (ETI-204), a high-affinity deimmunized monoclonal antibody. […]

Elusys awarded additional $50.2 million under an existing U.S. government contract to support final stages of development of ETI-204, for treatment of inhalational Anthrax

Media Center PRESS RELEASE 2012 ELUSYS AWARDED ADDITIONAL $50.2 MILLION UNDER AN EXISTING U.S. GOVERNMENT CONTRACT TO SUPPORT FINAL STAGES OF DEVELOPMENT OF ETI-204, FOR TREATMENT OF INHALATIONAL ANTHRAX Pine Brook, NJ – August 1, 2012 – Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing countermeasures for biodefense, announced today that it has been awarded […]